$4.15 -0.15 (-3.49%)
11/6/2009 4:00 PM

Amicus Therapeutics, Inc. (FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Current Price $4.15 Mkt Cap $93.97M
Open $4.27 P/E Ratio 11.67
Prev. Close $4.30 Div. (Yield) N/A (N/A)
Daily Range $4.15 - $4.31 Volume 25,533
52-Wk Range $3.68 - $13.50 Avg. Daily Vol. 182,000

FOLD News and Commentary

Related News and Articles

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

34 Outperform
16 Underperform
 

All-Star Members

14 Outperform
6 Underperform
 

Wall Street

3 Outperform
1 Underperform
 

Top FOLD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

PDTBiotech (90.26)
Submitted February 11, 2009

Piling in on zzlangerhans' excellent short call. Could cause significant pain before the woodshed trip due to the current and hopefully temporary lack of natural selection in the biotech industry. Shorts' enemy on this one is Amicus'… More

2 Comments | Reply | Report this Post
FOLD VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about FOLD.

Recs

0
Member Avatar SmallPimpin (98.78) Submitted: 10/6/2009 7:31:52 PM : Outperform Start Price: $5.26 FOLD Score: -22.87

Mmm...pharmaceuticals...

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar WPThatcher (69.32) Submitted: 10/6/2009 12:25:25 AM : Outperform Start Price: $5.82 FOLD Score: -30.95

I'm not green thumbing this stocks because I like the science behind the company. It's not about profits either, as the company has been unprofitable since its inception in 1992. They lost a third of their value today due to a disappointing Phase 2 clinical trial. They have a large cash position, but R & D will make sure that gets burned through. Plus they were downgraded today. I just think there will be a bounce of the 52-week low. I also like that insiders own over two-thirds of the company and don't seem to be dumping shares.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar mansloth (94.97) Submitted: 1/8/2009 8:32:13 PM : Outperform Start Price: $7.92 FOLD Score: -67.20

Therapeutics for protein folding diseases are going to be trendy over the next couple of years. More (and perhaps better) competitors with a focus on protein folding diseases will go public over the course of the next five years, while established ones like this will get gobbled up.

Report this Post 0 Comments | Reply | Permalink
View All 8 Pitches »

Leaderboard

Find the members with the highest scoring picks in FOLD.

Score Leader

zzlangerhans

zzlangerhans (99.36) Score: +86.16

Wow, this one took me by surprise. It's always nice when hard work and research pay off.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
qubit15 24.89 1/21/2009 Underperform NS $7.91 -47.53% +33.85% +81.39
anticitradeshort 25.36 4/20/2009 Underperform NS $8.75 -52.57% +26.54% +79.12
OOji 99.03 1/12/2009 Underperform 1Y $7.60 -45.39% +22.72% +68.11
BetapegAnalytics 92.09 8/13/2009 Underperform 5Y $9.91 -58.11% +6.57% +64.69
ArmstrongMan 93.66 7/24/2008 Underperform NS $14.92 -72.18% -13.87% +58.31
epc53 99.37 5/27/2009 Underperform 5Y $6.90 -39.86% +18.39% +58.24
mmmed 30.82 5/29/2009 Underperform 5Y $6.79 -38.88% +18.41% +57.29
bmoreNJ 41.46 8/28/2008 Underperform 3M $13.80 -69.93% -14.93% +55.00
PauvrePapillon 99.59 6/26/2007 Underperform 1Y $10.88 -61.86% -24.43% +37.43
SanDieguito < 20 12/20/2007 Underperform 1Y $9.99 -58.46% -22.99% +35.47 1 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackWedbush < 20 10/5/2009 Underperform NS $6.20 -33.06% +4.11% +37.18
TrackWedbush < 20 3/20/2009 Outperform NS $9.24 -32.90% +34.63% -67.53 10/5/2009 @ $6.20
TrackIcahn 27.08 12/31/2007 Outperform NS $10.75 -35.81% -35.69% -0.12 5/27/2009 @ $6.90 2 Comments
TrackPacificGrow 90.86 7/10/2007 Outperform NS $12.88 -67.78% -26.01% -41.77
TrackLazardCapit < 20 7/10/2007 Outperform NS $12.70 -67.32% -25.93% -41.39
TrackJPMorgan 78.71 7/10/2007 Outperform NS $13.00 -68.08% -25.95% -42.13

Featured Broker Partners